IN2014KN02335A - - Google Patents
Info
- Publication number
- IN2014KN02335A IN2014KN02335A IN2335KON2014A IN2014KN02335A IN 2014KN02335 A IN2014KN02335 A IN 2014KN02335A IN 2335KON2014 A IN2335KON2014 A IN 2335KON2014A IN 2014KN02335 A IN2014KN02335 A IN 2014KN02335A
- Authority
- IN
- India
- Prior art keywords
- patient
- risk
- reducing
- acting insulin
- therapeutically effective
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/22—Hormones
- A61K38/28—Insulins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61J—CONTAINERS SPECIALLY ADAPTED FOR MEDICAL OR PHARMACEUTICAL PURPOSES; DEVICES OR METHODS SPECIALLY ADAPTED FOR BRINGING PHARMACEUTICAL PRODUCTS INTO PARTICULAR PHYSICAL OR ADMINISTERING FORMS; DEVICES FOR ADMINISTERING FOOD OR MEDICINES ORALLY; BABY COMFORTERS; DEVICES FOR RECEIVING SPITTLE
- A61J1/00—Containers specially adapted for medical or pharmaceutical purposes
- A61J1/14—Details; Accessories therefor
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Organic Chemistry (AREA)
- Diabetes (AREA)
- Endocrinology (AREA)
- Zoology (AREA)
- Epidemiology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Immunology (AREA)
- Gastroenterology & Hepatology (AREA)
- Urology & Nephrology (AREA)
- Hematology (AREA)
- Heart & Thoracic Surgery (AREA)
- Cardiology (AREA)
- Obesity (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Emergency Medicine (AREA)
- Vascular Medicine (AREA)
- Biomedical Technology (AREA)
- Ophthalmology & Optometry (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medical Preparation Storing Or Oral Administration Devices (AREA)
- Investigating Or Analysing Biological Materials (AREA)
Abstract
The present invention relates to the use of use of a long-acting insulin, in particular insulin glargine, in a method of reducing the risk of progression to type 2 diabetes in a patient, a method of reducing the risk of a new angina in a patient and a method of reducing the risk of a microvascular event in a patient comprising administering to said patient in need thereof a therapeutically effective dosage of a long acting insulin, wherein said therapeutically effective dosage of said long acting insulin reduces said risks.
Applications Claiming Priority (6)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201261616768P | 2012-03-28 | 2012-03-28 | |
US201261619641P | 2012-04-03 | 2012-04-03 | |
US201261624598P | 2012-04-16 | 2012-04-16 | |
US201261645909P | 2012-05-11 | 2012-05-11 | |
US201261701911P | 2012-09-17 | 2012-09-17 | |
PCT/EP2013/056661 WO2013144273A1 (en) | 2012-03-28 | 2013-03-28 | Basal insulin therapy |
Publications (1)
Publication Number | Publication Date |
---|---|
IN2014KN02335A true IN2014KN02335A (en) | 2015-05-01 |
Family
ID=48044781
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
IN2335KON2014 IN2014KN02335A (en) | 2012-03-28 | 2013-03-28 |
Country Status (13)
Country | Link |
---|---|
US (1) | US20150065421A1 (en) |
EP (1) | EP2830650A1 (en) |
JP (1) | JP2015512908A (en) |
KR (1) | KR20150001757A (en) |
CN (1) | CN104334183A (en) |
AU (1) | AU2013241776B2 (en) |
CA (1) | CA2865823A1 (en) |
HK (1) | HK1201155A1 (en) |
IN (1) | IN2014KN02335A (en) |
MX (1) | MX2014011687A (en) |
RU (1) | RU2014143271A (en) |
SG (1) | SG11201405433XA (en) |
WO (1) | WO2013144273A1 (en) |
Families Citing this family (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2017108943A1 (en) * | 2015-12-23 | 2017-06-29 | Sanofi-Aventis Deutschland Gmbh | Cardiac metabolic effect of lantus |
EP3544683A1 (en) | 2016-11-28 | 2019-10-02 | Novo Nordisk A/S | Insulin degludec in cardiovascular conditions |
WO2018096164A1 (en) * | 2016-11-28 | 2018-05-31 | Novo Nordisk A/S | Insulin degludec for treating diabetes |
WO2018096163A1 (en) * | 2016-11-28 | 2018-05-31 | Novo Nordisk A/S | Insulin degludec for improvement of glycaemic control and reduction of acute and long-term diabetes complications |
Family Cites Families (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
GB0309154D0 (en) * | 2003-01-14 | 2003-05-28 | Aventis Pharma Inc | Use of insulin glargine to reduce or prevent cardiovascular events in patients being treated for dysglycemia |
EA201991014A1 (en) * | 2010-06-24 | 2019-09-30 | Бёрингер Ингельхайм Интернациональ Гмбх | DIABETES TREATMENT |
-
2013
- 2013-03-28 MX MX2014011687A patent/MX2014011687A/en unknown
- 2013-03-28 US US14/387,791 patent/US20150065421A1/en not_active Abandoned
- 2013-03-28 SG SG11201405433XA patent/SG11201405433XA/en unknown
- 2013-03-28 CN CN201380028029.4A patent/CN104334183A/en active Pending
- 2013-03-28 RU RU2014143271A patent/RU2014143271A/en not_active Application Discontinuation
- 2013-03-28 EP EP13713425.0A patent/EP2830650A1/en not_active Withdrawn
- 2013-03-28 CA CA2865823A patent/CA2865823A1/en not_active Abandoned
- 2013-03-28 WO PCT/EP2013/056661 patent/WO2013144273A1/en active Application Filing
- 2013-03-28 AU AU2013241776A patent/AU2013241776B2/en not_active Expired - Fee Related
- 2013-03-28 JP JP2015502348A patent/JP2015512908A/en not_active Ceased
- 2013-03-28 KR KR20147028987A patent/KR20150001757A/en not_active Application Discontinuation
- 2013-03-28 IN IN2335KON2014 patent/IN2014KN02335A/en unknown
-
2015
- 2015-02-13 HK HK15101611.0A patent/HK1201155A1/en unknown
Also Published As
Publication number | Publication date |
---|---|
JP2015512908A (en) | 2015-04-30 |
CN104334183A (en) | 2015-02-04 |
CA2865823A1 (en) | 2013-10-03 |
AU2013241776A1 (en) | 2014-10-16 |
EP2830650A1 (en) | 2015-02-04 |
AU2013241776B2 (en) | 2017-11-02 |
US20150065421A1 (en) | 2015-03-05 |
MX2014011687A (en) | 2015-05-11 |
HK1201155A1 (en) | 2015-08-28 |
KR20150001757A (en) | 2015-01-06 |
WO2013144273A1 (en) | 2013-10-03 |
SG11201405433XA (en) | 2014-10-30 |
RU2014143271A (en) | 2016-05-20 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
MY167234A (en) | Novel glucagon analogues | |
MX2020010693A (en) | Use of long-acting glp-1 peptides. | |
CL2013003454A1 (en) | Pharmaceutical composition for preventing or treating diabetes comprising a long-acting insulin conjugate and a long-acting insulinotropic peptide conjugate. | |
MY174727A (en) | Stable, protracted glp-1/glucagon receptor co-agonists for medical use | |
PH12014501702A1 (en) | Imidazopyrrolidinone compounds | |
PH12014501561A1 (en) | Therapeutically active compounds and their methods of use | |
IL227623B (en) | Nanoparticle compositions comprising a population of particles, for use in the manufacture of a topical medicament for treating a subject suffering from or susceptible to a condition or disorder associated with sweat glands and/or sebaceous glands | |
MX2013011175A (en) | Novel glucagon analogues. | |
EA201991014A1 (en) | DIABETES TREATMENT | |
MX356728B (en) | Pharmaceutical combination for use in the treatment of diabetes type 2. | |
MX366090B (en) | Pharmaceutical combination for use in inducing weight loss in diabetes type 2 patients or/and for preventing weight gain in diabetes type 2 patients. | |
MX363507B (en) | Methods of administering nitric oxide to arterial or arterialized blood. | |
WO2014153385A3 (en) | Methods of treating metabolic disorders | |
IN2014KN02335A (en) | ||
MX2016007682A (en) | Pharmaceutical composition comprising amorphous ivabradine. | |
WO2013083826A3 (en) | Glp-1 agonists | |
WO2014018763A3 (en) | Method of treating type i diabetes using apolipoprotein aiv | |
MX2014006990A (en) | Treatment of type i and type ii diabetes. | |
PH12014502497A1 (en) | New treatments of hepatitis c virus infection | |
UA111785C2 (en) | A COMPOSITION FOR THE TREATMENT OF Warts And A WAY OF TREATMENT | |
GB201217635D0 (en) | Use of short term insulin treatment to restore pancreatic function in type 2 diabetic patients who have become refractory through oral hypolgycaemic agents | |
MX2019008148A (en) | Use of long-acting glp-1 peptides. | |
UA79052U (en) | method for immunotherapy in exacerbations of chronic bronchitis in patients with insulin resistance | |
MX368505B (en) | Use of 3-carboxy-n-ethyl-n,n-dimethylpropan- 1-aminium or a pharmaceutically acceptable salt thereof in the prevention and treatment of diabetes. | |
UA69222U (en) | Method for reflexotherapy in patients with effects of traumatic brain injuries |